Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …

Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

The etiology of the common, sporadic form of Alzheimer's disease (sAD) is unknown. We
hypothesize that tau pathology within select projection neurons with susceptible …

Ageing is an inevitable event in the lifecycle of all organisms, characterized by progressive
physiological deterioration and increased vulnerability to death. Ageing has also been …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …